| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Internal Medicine (H.R., P.S., E.L.T.v.d.A., E.F.C.T.v.R., F.H.d.J., S.W.J.L., J.W.K.) and Reproduction and Development (A.O.B), Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
Address all correspondence and requests for reprints to: Henk Russcher, Erasmus Medical Center, Department of Internal Medicine, Room Ee593, Dr. Molewaterplein 40, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: h.russcher{at}erasmusmc.nl.
Context: Interindividual variation in glucocorticoid (GC)-sensitivity can be partly explained by polymorphisms in the GC receptor (GR) gene. The ER22/23EK and N363S polymorphisms have been described to be associated with lower and higher GC sensitivity, respectively.
Objective and Design: We examined the basis of this altered GC sensitivity by expressing GR(N363S) and GR(ER22/23EK) in COS-1 cells and investigating their transactivating and transrepressing capacities using a GC response element-luciferase reporter and a p65-activated nuclear factor
B-luciferase reporter, respectively. Furthermore, we evaluated the transactivating and transrepressing capacities of the GR in peripheral blood mononuclear lymphocytes of homozygous and heterozygous carriers of these polymorphisms by determining the maximum effect of dexamethasone on transactivation of the GC-induced leucine-zipper and transinhibition of the IL-2 gene by means of real-time RT-PCR.
Results: The effects of the polymorphisms in the GR gene previously observed in population studies were also detected at the level of gene expression. The ER22/23EK polymorphism resulted in a significant reduction of transactivating capacity, in both transfection experiments (14 ± 5%, P < 0.05) and peripheral blood mononuclear lymphocytes of carriers of this polymorphism (homozygous: 48 ± 6%, P < 0.01, n = 1; heterozygous: 21 ± 4%, P = 0.08, n = 3). The N363S polymorphism, associated with increased GC sensitivity, resulted in a significantly increased transactivating capacity, both in vitro (8 ± 3%; P < 0.02) and ex vivo (homozygous: 204 ± 19%, P < 0.0001, n = 1; heterozygous: 124 ± 8%, P = 0.05, n = 3). Neither the ER22/23EK nor the N363S polymorphism seemed to influence the transrepressing capacity of the GR.
Conclusion: The presence of these and other GC sensitivity-modulating polymorphisms may have consequences for the use of GCs in a clinical setting.
This article has been cited by other articles:
![]() |
H. Raef, E. Y Baitei, M. Zou, and Y. Shi Genotype-phenotype correlation in a family with primary cortisol resistance: possible modulating effect of the ER22/23EK polymorphism. Eur. J. Endocrinol., April 1, 2008; 158(4): 577 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. J. Finken, I. Meulenbelt, F. W. Dekker, M. Frolich, J. A. Romijn, P. E. Slagboom, J. M. Wit, and on behalf of the Dutch POPS-19 Collaborative Study The 23K Variant of the R23K Polymorphism in the Glucocorticoid Receptor Gene Protects against Postnatal Growth Failure and Insulin Resistance after Preterm Birth J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4777 - 4782. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. J. Lee, T. J. Creed, L. P. Schewitz, P. V. Newcomb, L. B. Nicholson, A. D. Dick, and C. M. Dayan CD4+CD25int T Cells in Inflammatory Diseases Refractory to Treatment with Glucocorticoids J. Immunol., December 1, 2007; 179(11): 7941 - 7948. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Jewell and J. A. Cidlowski Molecular Evidence for a Link between the N363S Glucocorticoid Receptor Polymorphism and Altered Gene Expression J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3268 - 3277. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Russcher, V. A S H Dalm, F. H de Jong, A. O Brinkmann, L. J Hofland, S. W J Lamberts, and J. W Koper Associations between promoter usage and alternative splicing of the glucocorticoid receptor gene J. Mol. Endocrinol., January 1, 2007; 38(1): 91 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. M. C. Koeijvoets, E. F. C. van Rossum, G. M. Dallinga-Thie, E. W. Steyerberg, J. C. Defesche, J. J. P. Kastelein, S. W. J. Lamberts, and E. J. G. Sijbrands A Functional Polymorphism in the Glucocorticoid Receptor Gene and Its Relation to Cardiovascular Disease Risk in Familial Hypercholesterolemia J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4131 - 4136. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Majnik, A. Patocs, K. Balogh, M. Toth, P. Gergics, A. Szappanos, A. Mondok, G. Borgulya, P. Panczel, Z. Prohaszka, et al. Overrepresentation of the N363S Variant of the Glucocorticoid Receptor Gene in Patients with Bilateral Adrenal Incidentalomas J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2796 - 2799. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Luczay, D Torok, A Ferenczi, J Majnik, J Solyom, and G. Fekete Potential advantage of N363S glucocorticoid receptor polymorphism in 21-hydroxylase deficiency. Eur. J. Endocrinol., June 1, 2006; 154(6): 859 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Russcher, P. Smit, E. F. C. van Rossum, E. L. T. van den Akker, A. O. Brinkmann, L. J. M. de Heide, F. H. de Jong, J. W. Koper, and S. W. J. Lamberts Strategies for the Characterization of Disorders in Cortisol Sensitivity J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 694 - 701. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |